JMP keeps Oscient at market outperform

Oscient Pharmaceuticals Corp. was reiterated by JMP Securities analyst Adam Cutler at its market outperform rating while continuing to track prescriptions for Factive and Testim each week. The first-quarter 2006 script data seem to be following the expected seasonal pattern. For the week ended Feb. 10, NDC reported that Factive total prescriptions were 9,296 (9,091 of which were new prescriptions), compared with 6,963 total prescriptions (6,745 of which were new) in the previous week. Total Testim scripts for the same week were 5,137 compared with 5,400 for the previous week. Shares of the Waltham, Mass., pharmaceutical company were down 3 cents, or 1.52%, at $1.95 on volume of 263,987 shares versus the three-month running average of 549,395 shares. (Nasdaq: OSCI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.